Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial
I'm PortAI, I can summarize articles.
Merck's experimental oral HIV treatment, combining doravirine and islatravir, proved non-inferior to Gilead's Biktarvy in a late-stage trial for adults with HIV-1 who hadn't received prior treatment. The safety profile was comparable, and Merck plans to present detailed findings at a medical meeting and submit applications to health authorities. The FDA decision on approval is expected by April 28, 2026. Doravirine is already approved in the U.S., while islatravir is still experimental.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments